Elan makes gains on ISEQ

Pharmaceutical company Elan saw its stock rise by over 15% following the announcement that it's multiple sclerosis drug Tysabri is expected to be put back on the market in the coming months after being withdrawn a year ago due to safety concerns.

The drug was taken off the shelves just over 12 months ago after three patients undergoing clinical trials developed a rare brain disease.